Elanco

What Elanco does

Elanco Animal Health (NYSE: ELAN) is a diversified global animal health company headquartered in Indianapolis, Indiana, that develops, manufactures, and commercializes pharmaceuticals, vaccines, parasiticides, feed additives, and monoclonal antibodies for both companion animals and livestock. The company operates two primary business segments: Farm Animal Health (cattle, poultry, swine, and aquaculture products such as Rumensin, Bovaer, Experior, and Pradalex) and Pet Health (dermatology products Zenrelia and Befrena, parasiticides Credelio Quattro and Advantage, vaccines TruCan Ultra, and mAb products Trutect). Underlying technology platforms include USDA-approved monoclonal antibody capabilities (Elanco is the only pet health company with two USDA-approved mAb products), proprietary PureFil vaccine technology, and the UpLook digital sustainability platform for measuring livestock environmental footprint. Elanco's roots trace to 1892 via Eli Lilly, with the company spinning out as an independent NYSE-listed entity in 2018 following the $7.6 billion acquisition of Bayer Animal Health.

Elanco makes money primarily through one-time sales of prescription and over-the-counter animal health products distributed via multiple channels: enterprise field sales to veterinarians and livestock producers, retail distribution (pet specialty, dollar, grocery, mass) for OTC items like the Advantage collar (priced below $25), government channels via USDA APHIS and the National Veterinary Stockpile for emergency-use products, and direct-to-consumer e-commerce through yourpetandyou.elanco.com. The company has recently begun generating licensing and royalty revenue streams, including the Neurizon Therapeutics monepantel agreement (up to $74.75M in milestones plus tiered single-digit royalties) and Syngulon bacteriocin licensing. Full-year 2025 revenue was $4.715 billion with Q1 2026 revenue of $1.371 billion (up 15% reported, 10% organic constant currency), and 2026 guidance has been raised to $5,010–$5,085 million. The company supports 11,000 SKUs across 17 manufacturing sites, employs 5,001–10,000 people, and serves more than 90 countries through 50+ country offices.

Name

Elanco

Legal name

Elanco Animal Health Inc.

Website

https://elanco.com

Company type

Public

Founded year

1954

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Elanco Animal Health is a global manufacturer of pharmaceuticals, vaccines, parasiticides, feed additives, and monoclonal antibodies for companion animals and livestock, selling to veterinarians, producers, retailers, and government agencies in over 90 countries.

Ownership category

akta.pro rank

Product category

Animal Health Pharmaceuticals

NAICS

Animal Food Manufacturing (31111)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

akta.pro secondary industries

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Animal Health OTC Retail (Parasite Control, Basic Care) (HLAMAIAJ), Antimicrobials & Anti-infectives (HLAMAEAE), Health Certification, Compliance & Traceability Support (Movement Certs, QA Programs) (AFACALAI)

Keywords

• Animal health pharmaceuticals
• Veterinary vaccines
• Livestock parasiticides
• Monoclonal antibody therapeutics
• Companion animal dermatology

Headquarters

HQ city

Greenfield

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Companion Animal Pharmaceuticals: Revenue from pet health products including Zenrelia, Credelio Quattro, Befrena, Trutect, and the Advantage flea/tick collar; serves pet owners and veterinarians in dermatology, parasiticides, and vaccines
2. Farm Animal Pharmaceuticals: Revenue from livestock health products including Experior, Rumensin, Bovaer, Pradalex, and cattle vaccines; serves livestock producers and veterinarians across cattle, poultry, swine, and aquaculture
3. Licensing and Supply Agreements: Revenue from licensing monepantel API to Neurizon Therapeutics and bacteriocin-based technologies to partners; milestone and royalty payments

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Elanco develops, manufactures, and markets a diversified portfolio of animal health products including pharmaceuticals, vaccines, parasiticides, feed additives, and monoclonal antibody therapeutics for companion animals (dogs and cats) and farm animals (cattle, poultry, swine, aquaculture). Its companion animal lineup targets dermatology, parasiticides, and vaccines (Zenrelia, Befrena, Credelio Quattro, TruCan Ultra, Trutect, Advantage collar), while its farm animal lineup addresses feed efficiency, disease prevention, and emissions reduction (Rumensin, Bovaer, Experior, Pradalex). Products are commercialized globally through veterinarians, livestock producers, retail/OTC channels, and government distribution in more than 90 countries.

Product overview

Elanco Animal Health operates as a diversified animal health company with two main segments: Farm Animal (livestock) and Pet Health (companion animal). The Farm Animal portfolio includes parasiticides (Rumensin, Bovaer, Experior), antibiotics (Pradalex), and digital sustainability tools (UpLook). The Pet Health portfolio centers on dermatology products (Zenrelia, Befrena), parasiticides (Credelio family, Advantage collar), vaccines (TruCan Ultra), and monoclonal antibodies (Trutect). Elanco launched Elanco Ventures in 2026, a $25M corporate venture capital fund targeting early-stage animal health innovation. Key recent product launches include TruCan Ultra Lyme-L4 vaccine (June 2026), Befrena monoclonal antibody (2025-2026), and Advantage collar (April 2026), all expanding the company's presence in the $1.3B canine dermatology market and broader pet health sector.

Differentiator

Problem solved

Functional benefit

Brands

• TruCan Ultra Portfolio: Canine vaccine portfolio including TruCan Ultra Lyme-L4 for Lyme disease and leptospirosis protection
• Befrena
• Zenrelia
• Credelio Quattro
• UpLook
• Bovaer
• Experior
• Rumensin
• Elanco Ventures

Products and services

• Zenrelia Canine dermatology product for allergic dermatitis; achieved blockbuster status on a trailing four-quarter basis (over $1 billion annually).
• Befrena (tirnovetmab) Anti-IL-31 monoclonal antibody injection for treating canine allergic and atopic dermatitis; provides itch relief within 24 hours with a 6–8 week dosing interval.
• Credelio Quattro FDA conditionally approved parasiticidal product for dogs providing broad protection against fleas and ticks; reached approximately 33% U.S. clinic penetration and approximately 40% market share in the endectocide space within months of launch.
• TruCan Ultra Lyme-L4 First and only 1/2 mL combination vaccine protecting dogs against both Lyme disease and leptospirosis, featuring PureFil Technology that reduces vaccination reactions; demonstrated 92.2% efficacy against natural Lyme infection in endemic areas.
• Trutect USDA-approved monoclonal antibody product for canine parvovirus; one of only two USDA-approved mAb products in Elanco's pet health portfolio.
• Advantage Collar for Dogs Over-the-counter flea, tick, and mosquito protection collar for dogs providing four months of continuous coverage via a time-release formula with pyriproxyfen; sold at suggested retail price below $25 through pet specialty, dollar, grocery, and mass retailers.
• Rumensin Cattle feed ingredient to improve feed efficiency and prevent and control coccidiosis; pioneered the ionophore class of animal health medicines.
• Bovaer Methane-suppressing feed supplement for cattle designed to reduce enteric greenhouse gas emissions.
• Experior Product for cattle that helps reduce ammonia emissions and improve sustainability outcomes; surpassed $200 million in sales with 80% growth in 2025.
• Pradalex FDA-approved fluoroquinolone injection for treating swine respiratory disease.
• UpLook Digital solution enabling farmers to measure on-farm environmental footprint, implement environmental solutions, and quantify improvements; integrated with livestock carbon insetting marketplaces. Over 1 million dairy cows and 2 million feedyard cattle enrolled.

Quantifiable outcome

• TruCan Ultra Lyme-L4 demonstrated 92.2% efficacy against natural Lyme disease infection in endemic areas and 100% efficacy in laboratory studies
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Indiana Corporate Partnership / BioHeartland IndianacoreStrategic or Co-development Partner · 22 June 2026Elanco participates in the BioHeartland Indiana initiative led by Indiana Corporate Partnership, unifying Indiana's more than $100 billion bioscience ecosystem under a shared brand. Elanco, along with Eli Lilly and Corteva, is showcased as a global leader in Indiana's life sciences sector at the BIO International Convention.
• One Health Innovation District / Purdue UniversitycoreStrategic or Co-development Partner · 18 June 2026Elanco is a founding/co-anchoring partner of the One Health Innovation District in Indianapolis, Indiana, alongside Purdue University. The initiative is dedicated to optimizing the health of people, animals, plants, and the planet, focusing on microbiome research, antimicrobial resistance, computational biology, and comparative genomics. Elanco Ventures will operate within this district.
• PetloveminorChannel Partner/ Reseller/ Distributor · 18 June 2026Petlove, Brazil's largest pet ecosystem, partners with Elanco as a major pharmaceutical supplier for its PetVet medication benefits program offering up to 40% discounts on approximately 140 veterinary medications including Elanco products in the R$ 3.2 billion Brazilian veterinary medications segment.
• British Egg Industry CouncilminorStrategic or Co-development Partner · 3 June 2026Elanco supports the rollout of AviPro Salmonella Duo vaccine following British Egg Industry Council's derogation granting use during lay. Elanco provides training and guidance programmes for producers, vets, and packers on in-lay Salmonella vaccination for extended production cycles.
• Syngulon SRLcoreStrategic or Co-development Partner · 25 March 2026Worldwide licensing agreement granting Elanco access to Syngulon's proprietary bacteriocin-based microbial selection technologies for animal health product development and manufacturing. The licensed technology enhances microbial stability and efficiency in industrial fermentation processes, supporting production of recombinant proteins and plasmid DNA.
• Coalition to Close the Protein GapminorStrategic or Co-development Partner · 24 March 2026Elanco is a member of the Coalition to Close the Protein Gap, a $40 million public-private initiative targeting America's annual charitable protein deficit. Coalition members include Tyson Foods, Cargill, Perdue Farms, and founding partners HHS and USDA, with HATCH implementing cold storage infrastructure and logistics to deliver up to 3 billion protein-rich meals annually.
• Neurizon TherapeuticscoreStrategic or Co-development Partner · 1 July 2025Global exclusive licensing agreement and long-term supply agreement with Neurizon Therapeutics for monepantel, the active pharmaceutical ingredient in Neurizon's lead candidate NUZ-001 for ALS and neurodegenerative diseases. Elanco provides GMP-compliant manufacturing supply; Neurizon pays up to $9.75M in milestones and up to $65M in sales milestones plus tiered single-digit royalties.
• SEC / Fair Fund InvestorsminorOthers · 1 November 2024In November 2024, the SEC issued a cease-and-desist order against Elanco for securities law violations, imposing a $15 million civil penalty distributed to eligible investors through a Fair Fund. This is a regulatory resolution rather than a commercial partnership.

Scale indicators16 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Zoetis: Zoetis is the largest pure-play animal health company globally, with a portfolio spanning parasiticides, vaccines, dermatology, diagnostics, and livestock pharmaceuticals that directly overlaps with Elanco's companion animal and farm animal segments. Both companies sell through veterinary channels and compete head-to-head in endectocides, vaccines, and monoclonal antibodies.
• Ceva Santé Animale: Ceva Santé Animale is a privately-held global animal health company headquartered in France, active in vaccines, pharmaceuticals, and companion animal products. It overlaps with Elanco in poultry and swine vaccines, small animal dermatology, and reproduction products, and is one of the few players with comparable multi-species global reach.
• Virbac: Virbac is a France-based global animal health company focused on veterinary pharmaceuticals, vaccines, and parasiticides for companion and food-producing animals. It is smaller than Elanco but addresses the same veterinarians and livestock producers with a comparable product mix in dermatology, parasiticide, and aquaculture adjacencies.
• Phibro Animal Health: Phibro Animal Health is a U.S.-listed animal health and nutrition company focused primarily on livestock (cattle, poultry, swine) with vaccines, antibacterials, and feed additives that directly overlap with Elanco's farm animal portfolio. Although smaller and less diversified into companion animals, it competes in the same livestock producer channel with comparable feed additive and vaccine economics.
• Vetoquinol: Vetoquinol is a France-based veterinary pharmaceutical company with companion animal and livestock products that overlap with Elanco's parasiticide, dermatology, and reproduction portfolios. It is a more focused mid-sized peer that competes in the same European and emerging-market veterinary channels as Elanco, and Elanco previously acquired select assets from Vetoquinol in 2020.
• Merck Animal Health: Merck Animal Health (MSD Animal Health outside the U.S.) is the animal health division of Merck & Co. and is one of the top three global animal health companies. It directly competes with Elanco in livestock pharmaceuticals, parasiticides, and aquaculture (where it bought Elanco's aqua business in 2024), and shares similar regulatory and R&D economics.
• Boehringer Ingelheim Animal Health: Boehringer Ingelheim's animal health business is a top-tier global animal health player with strong positions in vaccines, parasiticides, and pet therapeutics for both companion and farm animals. It acquired Merial and competes with Elanco across nearly all of Elanco's core categories, with comparable global manufacturing and distribution scale.

Emerging players

• Bimeda: Bimeda is a privately-held global animal health company headquartered in Ireland with a portfolio of veterinary pharmaceuticals, vaccines, and nutrition products across livestock and companion animals. It is smaller than Elanco and focused on generic and value-tier products, but it overlaps meaningfully in livestock parasiticides, anti-infectives, and reproductive products that Elanco also sells.
• Dechra Pharmaceuticals: Dechra Pharmaceuticals is a U.K.-headquartered specialty animal health company focused on companion animal endocrinology, dermatology, and specialty pharmaceuticals. It was taken private by EQT but remains highly comparable to Elanco in the dermatology and specialty therapeutics categories where Elanco is investing with Zenrelia and Befrena.

Broad incumbents

• IDEXX Laboratories: IDEXX is the global leader in companion animal diagnostics (in-clinic analyzers, reference lab services, practice software) and a broader incumbent in the veterinary channel. While not a direct pharmaceutical competitor, IDEXX sells into the same veterinary clinics that drive Elanco's companion animal prescribing volume, and its presence shapes channel economics and prescribing behavior that affect Elanco's products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/elanco
• Xx.com/Elanco

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elanco